BigPharma tries to distract from the main argument- Wants to stick Uncle Sam with their CRAP
Mort Zuckerman
Durlan...@yale.edu, Aa...@columbia.edu, gary_w...@nymc.edu,
scientifi...@ostp.gov, pkru...@princeton.edu,
Stanle...@fiu.edu, emcsw...@niaid.nih.gov, afa...@niaid.nih.gov,
Spin...@yahoogroups.com, kshe...@calea.org, fit...@gmail.com,
patrick.f...@usdoj.gov, model...@sbcglobal.net,
jdr...@nejm.org, let...@courant.com, Jgerb...@cdc.gov,
michae...@po.state.ct.us, con...@po.state.ct.us, executive-
edi...@nytimes.com, managin...@nytimes.com, news-
ti...@nytimes.com, biz...@nytimes.com, for...@nytimes.com,
nati...@nytimes.com, dv...@cdc.gov, brigidc...@optonline.net,
tr...@hotmail.com, illino...@aol.com, jle...@courant.com,
tinaj...@yahoo.com, jhorn...@fff.org, thomas...@usdoj.gov,
thoma...@po.state.ct.us, kur...@washpost.com,
georg...@washpost.com, p...@allegorypress.com,
commissi...@po.state.ct.us, brans...@comcast.net,
vts...@comcast.net, o...@po.state.ct.us, freet...@charter.net,
scott....@po.state.ct.us, govern...@po.state.ct.us,
attorney...@po.state.ct.us, randall...@usdoj.gov,
Robert....@yale.edu, edi...@greenwich-post.com,
harol...@yale.edu, sedm...@nswbc.org, rrmcg...@aol.com,
fr...@nytimes.com, dpr...@stmartin.edu
Cc: fra...@ucia.gov, dr-ahma...@president.ir,
eugener...@washpost.com, afa...@niaid.nih.gov,
bmi...@newstimes.com, tr...@hotmail.com, rast...@aol.com,
billc...@gmail.com, amcg...@rms-law.com, rjmu...@aol.com,
paulcrai...@yahoo.com, sidney_b...@yahoo.com,
criminal...@usdoj.gov, karla.d...@usdoj.gov,
christophe...@usdoj.gov, richar...@yale.edu,
harol...@yale.edu, james.p...@yale.edu, inq...@aldf.com,
ly...@idsociety.org, meganm...@theatlantic.com
Subject: (ABC News) BigPharma tries to distract from the main argument
Date: Jan 16, 2010 4:18 AM
ARICLE BELOW
=============================
Um, no.
BigPharma clearly has not much
going on in the REAL PRODUCT department.
Too many of their drugs are just plain
not drugs. None of the psychotropics
are drugs (Lithium is a natural product
and is neuroprotective:
http://www.ncbi.nlm.nih.gov/pubmed?term=%28%22lithium%22[MeSH%20Terms]%20OR%20%22lithium%22[All%20Fields]%29%20AND%20neuroprotection[All%20Fields]&cmd=DetailsSearch&log$=details
yet it's not even in the RDA.
All psychotropics are brain damaging
according to the published science:
http://www.actionlyme.org/BRAINDAMAGE.htm
Yale and duh DCF are an Rx recruiting grounds
for psychotropics studies (just ask Yale's
Tom McGlashan), with a net result of
mental retardation:
http://www.actionlyme.org/DCF_GRADUATARDS_SPEAK.htm
and adult/pediatric jail fodder (DCF's
drugging leads to street drug addictions).
This is where BigPharma makes most of their
money because the victims of these adverse
events are usually at the lowest end of
the socioeconomic totem pole, and as we
know, no one can trust a psychiatrist
with a drug trial.
Pharma did not heed the global warming/
infections signs. They're running out of
antibiotics, while screaming about drug
resistance in hospitals - which is more a
function of pigs - pigs in hospital whites
and tetracycline-laden swine lagoons:
http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=link&linkname=pubmed_pubmed&uid=19921873&ordinalpos=1&log$=relatedarticles&logdbfrom=pubmed
The likes of Pfizer would not come clean on what
they know about Plum Island:
http://www.actionlyme.org/PIIB.htm
Think about it. Pharma does not too
much in the discovery department.
Pfizer, rather than let the scientists
make the call on what is the direction
of research, simply buys up the companies
that have the patents on the drugs they want.
Cancer; B cell immortalizations; global
warming, infections; bogus vaccines;
ALS and mycoplasma; TLRs and dysimmunity
as a major cause of GI problems, too! arthritis,
gum disease and mycoplasma (or spirochetes);
drugs themselves that cause autoimmunity,
all kinds of borrelia in mosquitoes (not
OspA-Borreliosis), all over the world:
http://www.aaem.pl/pdf/16273.htm
Their whole world has been turned
upside down. There's been a seismic
shift in medical perception.
BigPharma got *crap* and they *KNOW* crap and
they're worried about not selling their
crap. So they want some kind of guarantee
that Uncle Sam is gonna buy their crap.
KMDickson
http://www.actionlyme.org
http://www.relapsingfever.org
===============================================
http://abcnews.go.com/Business/wireStory?id=9575325
Drug Companies Threatening to Oppose Health Bill
Drug firms threatening to end support for health overhaul in biotech
drug dispute
By ALAN FRAM
The Associated Press
WASHINGTON
The drug industry is threatening to end its support for President
Barack Obama's health overhaul effort because of a rift with the
administration over protecting brand-name biotech drugs from low-cost
generic competitors.
In an e-mail obtained Friday by The Associated Press, the president of
the Pharmaceutical Research and Manufacturers of America told the
trade group's board members that "we could not support the bill" if
the industry is given less than 12 years of competitive protection for
the expensive products.
Obama and House Energy and Commerce Committee Chairman Henry Waxman, D-
Calif., are leading the drive to shorten that period, which proponents
argue would be a boon to consumers.
"Please activate immediately all of your contacts," said the e-mail
from Billy Tauzin, the group's president.
The pharmaceutical industry has been a crucial supporter of Obama's
health effort, having spent many tens of millions of dollars on
advertising and lobbying in support. Drug companies should profit from
the millions of additional people who would be able to afford health
coverage under the legislation.
The threat comes with White House officials and Democratic
congressional leaders nearing an agreement on compromise legislation
reshaping the nation's health care system.
With a deal so close, it was unclear whether the partnership between
drugmakers and the administration was truly in jeopardy, or if the e-
mail represented an effort by the industry to pressure the White House
to drop its effort to shorten the period of competitive protection for
biotech drugs.
Any compromise bill, though, will face a nail-biting trip through
Congress, where Democrats got barely enough support when they pushed
initial versions of the bill through the House and Senate. If the drug
industry decided to pour money into advertising opposing the
legislation, that could give some lawmakers second thoughts about
supporting the bill.
Ken Johnson, a senior vice president of PhRMA, declined to comment on
the e-mail. But in a written statement, he said, "Fair data protection
of at least 12 years for new, innovative biologic medicines is
critically important to the future of medical progress in America."
In a written statement, Waxman said the overhaul should be "to help
struggling families, not to enrich the drug companies."
Last June, the industry agreed to actively support Obama's health
overhaul in an agreement with the White House and Senate Finance
Committee Chairman Max Baucus, D-Mont., to limit the cost to
drugmakers to $80 billion over next decade.
But as Democrats craft their compromise health bill, they have begun
looking for additional sources of revenue to pay for changes they are
making. That has included pressing the drugmakers to contribute an
additional $10 billion — another factor that might be part of PhRMA's
decision to threaten to withdraw its support.
Biotech drugs, manufactured from live tissue, are a fast-growing share
of sales for pharmaceutical companies worldwide and are seen as a
pivotal part of that industry's future.
The House and Senate versions of the health legislation give biotech
drugs 12 years of protection from generic competitors. Brand name
companies say they need that period to recoup their investments in the
products, which can be very expensive to develop.
The Obama administration has said seven years would be a reasonable
compromise. Some lobbyists have said Waxman was pushing to reduce the
12 years to 10 years or less.
A lobbying war on the issue has kicked into high gear.
Among groups whose members are calling the White House and
congressional leaders in support of the 12 years was the Massachusetts
Biotechnology Council, representing about 350 biotech firms.
Massachusetts is where a Republican is threatening to capture the
Senate seat long held by the late Sen. Edward Kennedy, D-Mass., in
next Tuesday's special election. That could make Obama reluctant to
support a policy that could anger employees of one of that state's
most important industries.
Senior presidential adviser David Axelrod said that Massachusetts Gov.
Deval Patrick called White House officials to raise concerns about
shortening the products' protections, "but he did not tie it to the
election at all."
Copyright 2010 The Associated Press. All rights reserved. This
material may not be published, broadcast, rewritten, or redistributed.
Copyright © 2010 ABC News Internet Ventures
"[Real] scientists are *fiercely* independent. That's the good
news."-- NIH's Top Fool, Anthony Fauci